King's Brief Interstitial Lung Disease questionnaire: Responsiveness and minimum clinically important difference

European Respiratory Journal

Volumn 54, Issue 3, 2019, Pages

  Nolan, Claire M ^a   Birring, Surinder S ^b   Maddocks, Matthew ^c   Maher, Toby M ^a,d   Patel, Suhani ^a   Barker, Ruth E ^a,d   Jones, Sarah E ^a,d   Walsh, Jessica A ^a   Wynne, Stephanie C ^a   George, Peter M ^a,d   Man, William D C ^a,d  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; EFFECT SIZE; FEMALE; FIBROSING ALVEOLITIS; HEALTH STATUS; HUMAN; INTERSTITIAL LUNG DISEASE; KING BRIEF INTERSTITIAL LUNG DISEASE QUESTIONNAIRE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PATIENT-REPORTED OUTCOME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY REHABILITATION; QUESTIONNAIRE; RECEIVER OPERATING CHARACTERISTIC; TREATMENT RESPONSE; MIDDLE AGED; MINIMAL CLINICALLY IMPORTANT DIFFERENCE; QUALITY OF LIFE; STATISTICAL MODEL; VERY ELDERLY; WALK TEST;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LINEAR MODELS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MINIMAL CLINICALLY IMPORTANT DIFFERENCE; PROSPECTIVE STUDIES; QUALITY OF LIFE; ROC CURVE; SURVEYS AND QUESTIONNAIRES; WALK TEST;

EID: 85071785133     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00281-2019     Document Type: Article

References (34)

1. Swigris J, Kuschner W, Jacobs S, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax 2005; 60: 588-594.
2. Wells A, Hirani N. Interstitial lung disease guideline. Thorax 2008; 63: Suppl. 5, v1-v58.
3. Visca D, Mori L, Tsipouri V, et al. Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respir Med 2018; 6: 759-770.
4. National Institute for Health Care and Excellence. Idiopathic pulmonary fibrosis in adults: diagnosis and management. 2013. www.nice.org.uk/guidance/cg163 Date last updated: May 2017. Date last accessed: January 10, 2019.
5. Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev 2014; 10: CD006322.
6. Dheda K, Lalloo U, Cassim B, et al. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol 2004; 23: 306-309.
7. Huppmann P, Sczepanski B, Boensch M, et al. Effects of inpatient pulmonary rehabilitation in patients with interstitial lung disease. Eur Respir J 2013; 42: 444-453.
8. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092.
9. Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 2008; 13: 394-399.
10. Perez-Bogerd S, Wuyts W, Barbier V, et al. Short and long-term effects of pulmonary rehabilitation in interstitial lung diseases: a randomised controlled trial. Respir Res 2018; 19: 182.
11. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082.
12. Dowman LM, McDonald CF, Hill CJ, et al. The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial. Thorax 2017; 72: 610-619.
13. Holland AE, Hill CJ, Conron M, et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008; 63: 549-554.
14. Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax 2012; 67: 804-810.
15. Patel AS, Siegert RJ, Keir GJ, et al. The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease. Respir Med 2013; 107: 1438-1443.
16. Patel AS, Siegert RJ, Bajwah S, et al. Rasch analysis and impact factor methods both yield valid and comparable measures of health status in interstitial lung disease. J Clin Epidemiol 2015; 68: 1019-1027.
17. Revicki D, Hays RD, Cella D, et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008; 61: 102-109.
18. Maddocks M, Kon SS, Canavan JL, et al. Physical frailty and pulmonary rehabilitation in COPD: a prospective cohort study. Thorax 2016; 71: 988-995.
19. British Thoracic Society. Quality standards for pulmonary rehabilitation. 2014. https://www.brit-thoracic.org.uk/ quality-improvement/quality-standards/pulmonary-rehabilitation Date last accessed: June 8, 2019.
20. Nolan CM, Maddocks M, Canavan JL, et al. Pedometer step count targets during pulmonary rehabilitation in chronic obstructive pulmonary disease. A randomized controlled trial. Am J Respir Crit Care Med 2017; 195: 1344-1352.
21. Quanjer PH, Tammeling G, Cotes J, et al. Lung volumes and forced ventilatory flows. Eur Respir J 1993; 6: Suppl. 16, 5-40.
22. Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581-586.
23. Nolan CM, Delogu V, Maddocks M, et al. Validity, responsiveness and minimum clinically important difference of the incremental shuttle walk in idiopathic pulmonary fibrosis: a prospective study. Thorax 2018; 73: 680-682.
24. Williams JE, Singh SJ, Sewell L, et al. Development of a self-reported Chronic Respiratory Questionnaire (CRQ-SR). Thorax 2001; 56: 954-959.
25. Kon SS, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med 2014; 2: 195-203.
26. Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407-415.
27. Kon SS, Dilaver D, Mittal M, et al. The Clinical COPD Questionnaire: response to pulmonary rehabilitation and minimal clinically important difference. Thorax 2014; 69: 793-798.
28. Raghu G, Collard HR, Anstrom KJ, et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 2012; 185: 1044-1048.
29. Swigris JJ, Fairclough D. Patient-reported outcomes in idiopathic pulmonary fibrosis research. Chest 2012; 142: 291-297.
30. Maher TM. Idiopathic pulmonary fibrosis. In: Kolb M, Vogelmeier CF, eds. Outcomes in Clinical Trials (ERS Monograph). Sheffield, European Respiratory Society, 2013; pp. 37-53.
31. Russell A-M, Sprangers MA, Wibberley S, et al. The need for patient-centred clinical research in idiopathic pulmonary fibrosis. BMC Med 2015; 13: 240-247.
32. Committee for Medicinal Products for Human Use. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. 2005. www.ispor.org/ workpaper/emea-hrql-guidance.pdf Date last accessed: July 15, 2016.
33. Stratford PW, Binkley JM, Riddle DL, et al. Sensitivity to change of the Roland-Morris back pain questionnaire: part 1. Phys Ther 1998; 78: 1186-1196.
34. Guyatt GH, Osoba D, Wu AW, et al. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002; 77: 371-383.